UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic ...

Plus, reviewers say this serum works wonders to revitalize the look and feel of your skin. “I have tried a couple of vitamin ...

Paid Advertisement In a world where personal appearance is increasingly valued, skin blemishes such as moles and skin tags ...

Find insights on AstraZeneca, Incyte and more in the latest Market Talks from the health-care sector.

Miraculously, you don’t have to travel to Korea to get yourself a bottle of the Bio-PDRN Caffeine Face Shot. You can head ...

The trial’s primary objective is to assess PALI-2108’s tolerability, pharmacokinetics and safety in healthy volunteers.

Scientists identified molecular targets of polycystic ovarian syndrome in rodents and humans, paving the way for improved ...

In the Phase III CALYPSO trial, eneboparatide demonstrated statistical significance in achieving albumin-adjusted serum calcium normalization while eliminating the need for active vitamin D and oral ...

LONDON, UK I March 17, 2025 I High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary ...